China Takayasu Arteritis Registry (CTA Registry)

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Takayasu arteritis (TA) is a chronic large-vessel vasculitis that mainly affects the aorta and its major branches. The epidemiology and pathophysiology of TA is still unclear in China, although many studies have been done. Our previous study supporting by National Natural Science Foundation of China indicated the cytokines such as hs-CRP, NT-proBNP and tumor necrosis factor-alpha (TNF-α) can be used to monitor TA activity, and HLA gene alleles were associated with TA in Chinese han population. Further investigations with larger samples are needed to fully understand the a pathophysiology of TA. The purpose of this study is to build a Chinese national registry system for TA to obtain real-world information, such as current status of characteristics, diagnosis, disease activity, the severity of disease, treatment and outcomes of Chinese TA patients. To analysis and development of effective disease monitoring and treatment strategies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 80
Healthy Volunteers: f
View:

• Age at disease onset \< 40 years. (Development of symptoms or findings related to Takayasu arteritis at age \<40 years)

• Claudication of extremities. (Development and worsening of fatigue and discomfort in muscles of 1 or more extremity while in use, especially the upper extremities)

• Decreased brachial artery pulse. (Decreased pulsation of 1 or both brachial arteries)

• BP difference \>10 mm Hg. (Difference of \>10 mm Hg in systolic blood pressure between arms)

• Bruit audible on auscultation over 1 or both subclavian arteries or abdominal aorta.

• Arteriogram abnormality. (Arteriographic narrowing or occlusion of the entire aorta, its primary branches, or large arteries in the proximal upper or lower extremities, not due to arteriosclerosis, fibromuscular dysplasia, or similar causes; changes usually focal or segmental)

Locations
Other Locations
China
Fuwai Hospital
RECRUITING
Beijing
Contact Information
Primary
Aimin Dang, MD,PhD
aimindangfw@gmail.com
+8610-88322131
Backup
Naqiang lv, MD,PhD
lvnaqiang@gmail.com
+8610-88322131
Time Frame
Start Date: 2016-08
Estimated Completion Date: 2026-07
Participants
Target number of participants: 1000
Related Therapeutic Areas
Sponsors
Leads: Aimin Dang

This content was sourced from clinicaltrials.gov